Absolute and relative changes in carotid intima-media thickness and atherosclerotic plaques during long-term antihypertensive treatment: Further results of the European Lacidipine Study on Atherosclerosis (ELSA)

Journal of Hypertension

Volumn 22, Issue 6, 2004, Pages 1201-1212

  Zanchetti, Alberto ^a,g   Bond, M Gene ^b   Hennig, Michael ^c   Tang, Rong ^b   Hollweck, Regina ^c   Mancia, Giuseppe ^d   Eckes, Lothar ^e   Micheli, Dino ^f  

^a UNIVERSITY OF MILAN   (Italy)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^d SAN GERARDO HOSPITAL   (Italy)

^e BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^f GSK   (Italy)

^g Ctro Interuniversitario Fisiol C   (Italy)

Author keywords

Antihypertensive drugs; Atherosclerosis; Carotid arteries; Hypertensions; Ultrasounds

Indexed keywords

ATENOLOL; HYDROCHLOROTHIAZIDE; LACIDIPINE;

ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ARTERY WALL; ARTICLE; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CALCULATION; CAROTID ARTERY BIFURCATION; CLINICAL TRIAL; COMMON CAROTID ARTERY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; HYPERTENSION; INTERNAL CAROTID ARTERY; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

EID: 2642554650     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004872-200406000-00022     Document Type: Article

References (16)

1. Zanchetti A, Bond MG, Hennig M, Neiss A, Mancia G, Dal Palù C, et al. Calcium antagonist lacidipine slows down progression of asymptomatic carotid atherosclerosis. Principal results of the European Lacidipine Study on Atherosclerosis (ELSA), a randomized, double-blind, long-term trial. Circulation 2002; 106:47-52.
2. Zanchetti A, Bond MG, Hennig M, Neiss A, Mancia G, Dal Palú C, et al. Risk factors associated with alterations in carotid intima-media thickness in hypertension: baseline data from the European Lacidipine Study on Atherosclerosis, J Hypertens 1998; 16:949-961.
3. Laird NM, Ware JH. Random-effects models for longitudinal data. Biometrics 1982; 38:963-974.
4. Chakravarti IM. Confidence sets for the ratio of means of two normal distributions when the ratio of variances is unknown. Biometr Zsch 1971; 13:85-94.
5. Nelder JA, Wedderburn RWM. Generalized linear models. J R Stat Soc A 1972; 135:370-384.
6. MacMahon S, Sharpe N, Gamble G, Clague A, Murchu CN, Clark T, et al. Randomized, placebo-controlled trial of the angiotensin-converting enzyme inhibitor, ramipril, in patients with coronary or other occlusive arterial disease. J Am Coll Cardiol 2000; 36:438-443.
7. Simon A, Gariépy J, Moyse D, Levenson J. Differential effects of nifedipine and co-amilozide on the progression of early carotid wall changes. Circulation 2001; 103:2949-2954.
8. Zanchetti A, Agabiti-Rosei E, Dal Palù C, Leonetti G, Magnani B, Pessina A. The Verapamil in Hypertension and Atherosclerosis Study (VHAS): results of long-term randomized treatment with either verapamil or chlorthalidone on carotid intima-media thickness. J Hypertens 1998; 16:1667-1676.
9. Pitt B, Byington RP, Furberg CD, Hunninghake DB, Mancini GBJ, Miller ME, et al. Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. Circulation 2000; 102:1503-1510.
10. Lonn EM, Yusuf S, Dzavik V, Doris CI, Yi Q, Smith S, et al. Effects of ramipril and vitamin E on atherosclerosis: The Study to Evaluate Carotid Ultrasound changes in patients treated with Ramipril and vitamin E (SECURE). Circulation 2001; 103:919-925.
11. Hedblad B, Wikstrand J, Janzon L, Wedel H, Berglund G. Low-dose metoprolol CR/XL and fluvastatin slow progression of carotid intima-media thickness: main results from the β-Blocker Cholesterol-Lowering Asymptomatic Plaque Study (BCAPS). Circulation 2001; 103: 1721-1726.
12. Cominacini L, Garbin U, Pasini AF, Davoli A, Campagnola M, Pastorino AM, et al. Oxidized low-density lipoprotein increases the production of intracellular reactive oxygen species in endothelial cells: inhibitory effect of lacidipine. J Hypertens 1998; 16:1913-1919.
13. Cominacini L, Pasini AF, Pastorino AM, Garbin U, Davoli A, Rigoni A. Comparative effects of different dihydropyridines on the expression of adhesion molecules induced by TNF-alpha on endothelial cells. J Hypertens 1999; 17:1837-1841.
14. Taddei S, Virdis A, Ghiadoni L, Magagna A, Pasini AF, Garbin U, et al. Effect of calcium antagonist or beta blockade treatment on nitric oxide-dependent vasodilatation and oxidative stress in essential hypertensive patients. J Hypertens 2001; 19:1379-1386.
15. Soma MR, Donetti E, Seregni R, Barberi L, Fumagalli R, Paoletti R, Catapano AL. Effect of lacidipine on fatty and proliferative lesions induced in hypercholesterolaemic rabbits. Br J Pharmacol 1996; 118:215-219.
16. Cristofori P, Lanzoni A, Quartaroli M, et al. The calcium-channel blocker lacidipine reduces the development of atherosclerotic lesions in the apoE-deficient mouse. J Hypertens 2000; 18:1429-1436.